- Home
- ALGS vs BTAI Comparison
ALGS vs BTAI Comparison
Compare ALGS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | BTAI |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | 82 | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 35.8M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALGS | BTAI |
|---|---|---|
| Price | $4.90 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $39.33 | $23.00 |
| AVG Volume (30 Days) | 121.7K | ★ 590.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | 75.63 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,186,000.00 | N/A |
| Revenue This Year | $32.20 | $197.82 |
| Revenue Next Year | $4.71 | $910.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.01 | $1.01 |
| 52 Week High | $13.69 | $8.08 |
Technical Indicators
Market Signals| Indicator | ALGS | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 43.30 |
| Support Level | N/A | $1.05 |
| Resistance Level | $6.82 | $1.39 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 7.63 | 10.14 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.